Clinical

Kerry Rogers, MD, outlines the cardiovascular risks of prolonged BTK inhibitor therapy in CLL and the major sequencing questions that remain unanswered.

Selinexor plus ruxolitinib showed greater spleen reductions and an early survival signal in JAK-naive myelofibrosis, Claire Harrison, MD, explained.

Our annual ASCO recap issue will have a new section, "On the Horizon," featuring emerging science, therapies, and technology.

Epcoritamab shows high rates of first-line response and MRD negativity in older patients with chemo-ineligible DLBCL, whether used alone or with R-mini-CHOP.

In 'From Promise to Practice: Overcoming Access and Administration Challenges for Bispecifics in RRFL,' Ryan Haumschild, PharmD, MS, MBA, CPEL delves into the following critical question:

In this episode, 'Epcoritamab in RRFL: Efficacy Data, Administration Considerations, and the Pharmacist's Operational Role,' Ryan Haumschild, PharmD, MS, MBA, CPEL explores the following questions:

Asthma biologics were associated with sustained reductions in exacerbations after 2015 across demographic and clinical subgroups in a large cohort study.

The phase 3 SigVie-002 trial showed sigvotatug vedotin missed the OS end point, but the second-line subgroup showed a survival trend and manageable safety.

Joseph K. Han, MD, discusses upstream biologics, verekitug, and the future of chronic rhinosinusitis with nasal polyps treatment.

Patients with familial pulmonary fibrosis had faster FVC decline and were more likely to have a UIP pattern, supporting family history as a prognostic tool.

Patients with early relapsing multiple sclerosis (MS) were able to switch to ocrelizumab after suboptimal responses to other disease-modifying therapies.

Clinicians battle insurance formularies, using evidence, step-therapy strategy, and two‑week outcome tracking to secure affordable psychiatric meds.

Clinicians navigate insurance formularies, prior authorizations, and step therapy—using 14‑day check-ins and PHQ‑9 data to win better meds.

Armored DLL3 CAR T-cell therapy from Legend Biotech/Novartis shows early responses in small cell lung cancer and neuroendocrine tumors, according to presentation at ASCO.

Hidden costs, travel, and dilation can derail DME care, but clinicians can build adherence plans that keep working adults on vision-saving therapy.

Experts warn extrapulmonary neuroendocrine carcinomas are often missed; faster pathology, rapid referrals, and early treatment improve survival.

Rare neuroendocrine carcinomas outside the lung often go missed; expert pathology and rapid referrals enable earlier treatment and better outcomes.

Anita Kumar, MD, of Memorial Sloan Kettering Cancer Center details evolving mantle cell lymphoma care: ECHO acalabrutinib-BR and chemo-free zanubrutinib BOVen triplets challenge standards.

These phase 3 studies are evaluating outcomes among patients living with polycythemia vera, myelofibrosis, and essential thrombocythemia.

Investigators described the combinations as a potential new standard of care in second-line HR+/HER2− advanced breast cancer.

Current sickle cell disease (SCD) trial eligibility criteria exclude most adults, with only 9.9% meeting inclusion thresholds, Julie Kanter, MD, says.

Zobair Younossi, MD, explains why fibrosis, not steatohepatitis resolution, best predicts MASH outcomes in trials.

Joseph K. Han, MD, discusses verekitug, unmet needs in CRSwNP, and why better biologic therapies remain necessary.

Phase 1 BALLI-01 trial results showed promising UCART22 activity in R/R B-cell ALL, with higher remission rates after a manufacturing change.